Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 26, 2013

View Archived Issues

Researchers at Janssen R&D Ireland divulge novel antibacterial agents

Purdue Pharma prepares new TRPV1 antagonists

Sihuan Pharmaceutical cleared to conduct study of DPP IV inhibitor in China

BioMarin presents clinical results for two novel enzyme replacement therapies

Shimojani acquires exclusive worldwide license to new stroke therapy

Okairos commences phase I trial of RSV vaccine

Boehringer Ingelheim describes antidote to dabigatran

Dual oxidase 1 linked to reactive oxygen species release during ischemia

ACE gene polymorphism studied in Pompe's disease response to treatment

New antibacterial agents patented by Actelion Pharmaceuticals

Tempero Pharmaceuticals divulges novel RORgamma modulators

Institute for OneWorld Health presents new CFTR channel inhibitors

New study evaluates CNDO-201 in psoriasis

Cubist Pharmaceuticals and Adynxx enter acquisition agreement

Phase III DISCOVER 2 study in ABSSSI meets endpoints

Ampio Pharmaceuticals modifies Ampion IND to include a dose-escalation study

First patient dosed in phase Ib study of AVX-470 in ulcerative colitis

Ligand receives milestone payment from RE-021 collaboration

MediciNova's MN-166 gets fast track designation from FDA

SBC-103 shows dose-dependent HSD reductions in MPS-III B mouse model

Regorafenib granted priority review in Japan

FDA grants QIDP and fast track designations to Furiex's broad-spectrum antibiotic

LEO Pharma and 4SC Discovery enter research and license agreement

Regeneron presents first-in-human results for dupilumab

Mirabegron launched in the U.K. for treatment of overactive bladder

Dynavax Technologies receives complete response letter for Heplisav

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.